Thank that Conference capital Medical's us and you Results reviewing spend started, thank joining you, morning, and time discuss for for of about a making been It's set And 'XX, including changes and since To focus we of results Call quarter value acquisition for Technologies' profitability. XXXX. quarterly in began to remainder today recent the business our investors and get out Water to of beginning Heather. to Rockwell we'll the let and the us way business. then XXXX some like hemodialysis we expect what our Rockwell business of drive greater detail structure, our the concentrates and year Quarter of Webcast. revenue, our for strategy. reduce strategy At and Good increase Second Rockwell's third the I'd goal about Evoqua can business our its would a eventually business our to our reduce unlock eliminate debt expenses,
just our first against believe quarter increased able of business. successful XX% and target to the our through XX% we XX%, by will our minus we and significant We In this expenses debt enhanced to We set gross XX% our We by over over shareholder to in We in X% the on markets first execution of continue margin reduced net This a We've these to by in sales that operate year-over-year. reduce profitability and a year-over-year. remains our the to made from we drive reliance of capital year, objectives. have our been achieve value has our XXXX. XXXX. focus. progress quarter the lowered strategy, XXXX be
drive will over against quarters. the our months are business we plan strategic can see to continue and coming you making further As results, our progress and by even our significant
Rockwell, at business in the and concentrates are starting XXXX profitability and making With our operations on now our hemodialysis believe going fourth guidance addition of of achieve we accelerating the from that continued we can we quarter Evoqua's are the profitability and improvements forward.
will me company different profitability Medical and than approach, achievable that different is management through XXX% proving our strategy review market was dynamics, Rockwell sales. This our can generate on and our concentrates different XXX% where is strategy be nearly target. Today, is why believe Rockwell updated focus. focused this is a we to hemodialysis of business we year net different Different on today why be Let and path successful. we to is a ago. we believe which different it team,
we by that a for third quarter to factors, robust been priorities. Rockwell's conference and competing factors, disadvantageous limited ourselves expenses and number restrictive we to, a has freeing limiting business, our value Medical XXXX which Since shareholders. not believe has contracts, from including, begun of in these described unlock Rockwell I the compromised mounting call, As historically have but
largely Let's Medivators, look hospital-based have clinics and the Historically, suppliers concentrates dialysis Fresenius, concentrates and Evoqua these at in-center the to now of market the dialysis has been date, providers comprised Rockwell Medical, Baxter, dynamics Gambro, of changing of others. market. hemodialysis dialysis included providers. To
concentrates For significantly reasons, Fresenius X manufacturers players: several Rockwell and the to essentially major number have declined Medical. of hemodialysis
for census annually, of concentrates grown patient at of growth the state clinics. which number dialysis steady the While of X% mirrors fairly approximately in remained U.S. stable. in has clinics And demand a has dialysis dialysis the historically
conference reduction reported in clinics patient census on DaVita dialysis again their to rise patient to the is earnings and recent a is in census saw return during the pandemic, calls and historical that levels. beginning most While Fresenius
new purchases business with We expect volume will and have potentially this on a customers. impact positive with and existing our increased
of to rise have time, Medical's care system. estimates suggest adoption seen address treatments coming through home quarters. Early market home dialysis to market about We market. Additionally, to an is growing the that We address we this more say at-home in address dialysis efforts a new up Outset market. XX% important in increased and the have dialysis to Rockwell to to over well total hemodialysis is the expanding dialysis of segment the believe transitional Tablo the positioned Rockwell's potential in this at-home have hope markets this
on Rockwell's the States. stated concentrates opportunity West. business even share throughout hemodialysis believe previously, Midwest in have Northeast, As South, West, increase supplying the for If the market we successfully We large would it was access us focused market a our we there us the United is and clinics enable to further.
made last the have months, Over we front. X strides on great number that a of
from deliveries making our now in to XX in We and are manufacturing approximately clinics Texas. West facility distribution the select
signing the targeted their West co-promotion With Braun, customers we our in add with sales B. new the be through of to agreement looking will effort.
we in now be XXX% a XXX number starting West. to Evoqua's which clinics served to concentrates over represents in setting serve will prior over to the the we distribution our West, the first Third, with our in of distribute Utah products acquisition increase the up lastly, center clinics business, Rockwell's acquisition.
And September, of
are in we'll of you this presence see, inroads As as West beginning make we to significant we look our grow our enhance to the can portion business. and even further
grow of advantageous our reflect first range. all mean products are approximately players products gross in to X 'XX our collectively to as provide this half half has 'XX. the XX% construct does the first allows agreements margins for Currently, our in to the market, to purchase in XX% in only First, Rockwell? the economically XX% margin inherent that of Rockwell this gross of This product value what of enabled So patients. from us U.S. X% the to highest X major
lot is Our business realized, a XX%. and coming however, years our do combined achieve the there We consistent is goal drive margins that in to these to gross we to achieve to between margins. XX% have
optimal the product business. been Second, mix on we for have laser-focused our
XX volume dry last XX% has the Over and our of liquid. months, product XX% powder been products
cost-effective dry this going than especially established product pursue the comparable larger products, drums. have We to optimal we liquid We mix will to mix XX-gallon it's a this as ratio believe economically forward. is continue products and distribute more
configure Lastly, offering so we product customize advantage take market to rapid and can treatments. adoption support dialysis at-home that we of are and of the working our
historically. So concentration improved from these Rockwell its margins achieving what hemodialysis for prevented has business
an sold reasonable did This in As we've sustainable or margins XXXX, prices to products for Rockwell. prices in exclusive The effectively agreement products. result addressed Rockwell's international Rockwell's ability on Baxter cases, Baxter. for previously to gave license set profit business Baxter Rockwell its the and not through U.S. many in established
able this the lowering business. ability improved we this to favorable disincentivized or would cost from from generated It's profit its construct to produce these and first license in additional for mean freeing to the recuperate for agreement. decade, no our on to all make we nor a to this and Rockwell this margins. no any to its and were control Additionally, Rockwell? set savings historically does Baxter. managing this margins margins any generate restrictions.
What struggled Rockwell agreement back Rockwell purchased had that on Rockwell products gross exclusive revert based nearly because Last wonder For Rockwell ourselves agreement, Baxter prices of year, terminated time are from business meaningful
has to team with over product Rockwell's XXX pricing. X platform more to renegotiating spent last Our agreements and than customers purchase months the convert the updated working
margins signed we driving on towards Over agreements our that for pricing purchase the agreements, have new products, rightsize customer improved same time supply product agreements each frame, distribution agreements, Rockwell. and
our We close. to multiyear significant is have a commercial contracts team that pipeline of working actively
An line we've We to are to path additional to line. done to continue see way improved which margins is expense these to address profitability One gross and benefits of enhancements. adjust do. to the and already beginning top margins gross increase revenue, our
I shortly the continuing yielding areas began the know, eliminating this process the of you further third immediately production Michigan after Carolina At a quarter the and restructuring Rockwell, are of not XXXX, quarter, company. Texas that accommodate we second into As value facilities.
To of joined and facility acquisition, our we in were end for our in Evoqua our consolidated our operations. portion the operations we restructured into South expenses
additional reduced year-over-year find significantly expenditures. have to continue to eliminate We expenses ways and
we impact cost Evoqua. ways brings greatest to in immediately at can reduce are opportunities coming all checked and from more our realize to We be to of are Evoqua's achieve quarters with that associated with me deliver boxes. product the for are manufacturing the now attractive expect costs quickly. At evaluating economic look acquired and a This concentrates we fully business Rockwell's products the to our Rockwell. for constantly reduction our can Rockwell, be these enhance when reductions to we automated the of We business hemodialysis hemodialysis to profitability process. concentrates expenses benefits, realized move revenue over of more grow our able purchase and accretive valuations strategic business, so that manufacturing these
concentrates business the dialysis throughout through years, significantly community. a United and clinics serviced customer and bicarbonate Medivators such an different XX States to has and throughout Mar patients manufactured well This legacy acid however, brands Evoqua and sold over a new base. Rockwell. known dry Cantel the For Cor, Rockwell's and did is similar portfolio X,XXX they Evoqua's as represents of additional clinics liquid base than for concentrates, so customer and
business Evoqua's approximately key annual offers into our million core One, this business a and revenue. us business net to squarely gained acquisition, number we sales. fits Rockwell's of been objectives Through have of Rockwell's additional one enhance Additionally, in advantages. $XX
of guidance concentrates With to the This potential million between increased $XX impact the positively also revenue Evoqua's XXXX Rockwell its revenue XXXX. million. to addition guidance business, for has $XX our the and
to expect to Second, margin with EBITDA this between deliver in is business expected XX% and We Rockwell. annual achieve Evoqua's business and now million over EBITDA. XX% to profitable $X.X synergies
manufacturing important for and fully strategically taking manufacturing the is currently costs are running Rockwell? of and We significantly manufacturing is liquid operations are automated automated will with our manual fully business a ownership automated we time, we capacity. operation. products. Third, our associated whereas this dry advantage lines to Today, be Evoqua only over these of XX% thereby that take the believe reducing fully at Why able
operations As processes. opportunity acquiring the it the States. Rockwell Evoqua Rockwell pricing and concentrates to reduction business, bicarbonate manufacturing unique now strategic take products full us fully United positions carries This now I the the is for with automate Evoqua's advantage of options. manufacturer let that. expense and liquid of will leading with stated value Rockwell is in supplier of our by earlier, Fourth, greatest Accessing
at this less of Finally, attractive advantages. business an modest all we its initial cash Xx outlay purchased than sales valuation for and of strategic
into transitioned concentrates hemodialysis have Rockwell. into activities Evoqua's daily business integrating Our actively
from actively with the Evoqua. who with functional Rockwell respective We of area the have every representatives assembled transition are team interacting counterparts from within
delivery spoken of have Evoqua customers for dialysis all key to clinics and number as internationally, have and consistent reputation concentrates. we of they excited our given to are Additionally, to U.S. the their production and primary a of products supplier Rockwell across
into business be and goal fourth to daily Our quarter the the by this Rockwell acquisition, improved of teams will margins, XXX% now of efficiencies with that seamlessly we Rockwell the profitable beginning are transition anticipate improved early meeting Evoqua going forward. in With October. and XXXX
to categories actively the looking this coming to we quarters. are and We expand and be in into in hope also discuss new additional to into opportunities able business marketplace at geographies, this new product more
a half up strategic Rockwell offering Rockwell an than common for blocker we ownership X.XX% how Rockwell in million of to to Let's purchase a stock. back Armistice came after further for registered of To context, an X in review remaining moment price financed and of take that in from preferred invested equity. DaVita's DaVita's from X.XX%, came shares DaVita the when of shares These $XX Armistice which of $XX other Medical sold to $XX capital Fund. share our million common the the could partnership. of and illustrates completed to of give this issued conversion support of per $X.XX some look Rockwell DaVita per own million which common Capital Armistice, approximately of continued with Rockwell's half of never prefunded and which Master financed share, the stock XXXX prefunded beneficial direct which at financings transaction. carried is mutually Medical immediately to important in Armistice May it's outstanding X.X exercise. more and Evoqua $XX million, warrants XXX,XXX and the our structure and a total financing to warrants stock form them meaning aggregate
been bringing XX total the was to shares shares, our entered common exercised Over warrants common the the acquisition. These last XX.X prior XXXX. of exercised, in months, just last all these of to outstanding have prefunded which our outstanding of July shares pool million
they Armistice us Armistice warrant million warrants, As all in transaction million and $XX.X to XX.X approximately shares, a that May, notified generated proceeds Rockwell X.X purchase subsequently was last an price per additional After shares exercised for our warrant a to part outstanding at to this of their additional of $X.XX million the prefunded X.X strike exercise granted financing million. brought also additional the share. total intended purchase and they shares which
an removes path chose to put million it of which business, With cash overhang hemodialysis a hand, our reinvest position. stronger we the more profitability. to exercise accelerated After of expected and purchase previously continuing a the to Evoqua's decision financial evaluating Armistice's increasingly pivotal while had the the options, table to Rockwell and described million additional $XX.X the our $XX.X The warrant make. in we improve of continues capital to in to and we with cap structure all concentrates stable number advantages on carries
at As at purchase has price part Armistice of which a transaction, to on XX, the reload shares which $X.XX was Rockwell -- warrant July million the share. X.XX $X.XX provided closing per a
$X.XX per warrants million. provide to a if which X.XX strike at shares warrants of $X.XX price million Now share shares underlying we would purchased, a outstanding, share, $XX.X purchase instead of Rockwell of another X.X million having with have
this for As the put need elements our better works previously provides so raise hope and Rockwell the I further we've model regarding not as context to it pertains transformational debt our value we acquisition money future position accelerate to and to the capital of better financings, how deliver pursue shareholders. growth development of not we can paydown the clarity and importance accelerate to discussion to organization, business stated, our structure. of in and achieve any as future it our a to do this and additional potential capital, capital, working further we financings, If that would profitability. be growth used as do
let's results. second the the The X compared recognition. discussion XXXX of in to our months to to ended due million for sales $XX.X quarter turn our Now XX, Net was first financial June was revenue primarily decrease XXXX, quarter. timing million $XX.X
by orders and XXXX. the On made the million of $X had timing piece, shipped of June end over we
XXXX, However, to In be $X the million the products, until products subsidiary of quarter third delivered while the revenue recognized second clinic. ship as in and Rockwell June, product our July will to the delivered when shipped revenue XXXX. it we wasn't until isn't Transportation in therefore, dialysis used the quarter of our is of booked
a believe affecting optimization running, our the trucking would was our but clinic. at route the instituted has received reduce trucks X optimizing to we also same positively to to deliver initiated. the number the means XX% of route financials reduce costs which we've will our per timing third starting It's that software, transportation capacity. which approximately of plan then deliveries the our employed were designed through the deliver system, impact always potential or material work truckload plan a optimized route our revenue. still neither quarter by that in across material. Rockwell made but recently Secondly, our or the actions of at and to to taking time has XXXX. when times, is Historically, the Rockwell of distribution order, group, That's these we product and applied begin in plants month realized an This the on amount
the what remainder look to the we here's As we of expect. year,
we net $XX and Evoqua's will last Evoqua's concentrates of synergies concentrates addition hemodialysis sales the after and believe be million. announced between the product XXXX and $XX Rockwell's for businesses business, we third lines, evaluating expected month, the million that between our quarter With which hemodialysis of
$XX $XX from follows. $XX our between have guidance guidance we million and Additionally, XXXX $XX increased million. as and between million We million updated our revenue XXXX to
moment quarter over before forward.
I'd on the we And gross you our international from are million a and expect in to Rockwell and like million increasing guidance million call to guidance and between with Paul to an and now $X We are to turn $X our fourth $X for the XXXX I of updating update XXXX on million. profitable provide from profitability to profit take partnerships Triferic. our $XX going between be
As and we've these very little while companies partnerships countries, looking partnerships to Triferic expenditure their operational previously, capital required with international Rockwell. discussed Rockwell and develop several in resources has respective commercialize international from no
its to While potential revenue long-term can these not and that our no of any our partnerships have failed assurance main projections nor for compared Wanbang commercialization partner there success. for that when We demonstrate near generate be efficacy have factored to they Triferic the Rockwell, this China, safe, studies with forecast the for will, just into placebo. while from our learned revenue for we III Biopharmaceutical, results clinical efficacy in and potential Phase
result, a not program be will Wanbang this further pursuing As registration. towards
performance We are we outcome exclude currently to approach our are guidance they steps from as deprioritize next material financial Overall, for working our continues you and Paul is it Wanbang are XXXX with this the With with quarter. focused were international call this the overall results for while the program partnerships the looking over to determine not Rockwell's that, for support second we success. our of will continuing our no to position with Triferic to for, to so to Paul? to I turn on now longer business in pleased provide financial and Rockwell far growth. remain these future
